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Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death world-wide, and the age-adjusted incidence rates have doubled over the past two decades (1, 2) . Despite the advancement of therapeutic modalities including surgery and chemotherapy, the overall survival (OS) of patients with HCC remains unsatisfactory because of the high rate of recurrence and metastasis (3, 4) .
Sorafenib, a novel multikinase inhibitor, is the only targeting molecule which has recently been approved by Food and Drug Administration for the treatment of unresectable HCC. Nevertheless, sorafenib only showed limited survival benefits in the late stage HCC patients, and has no strong efficacy on tumor metastasis, which is the most common cause of death from HCC (5, 6) . Hence, there is a pressing need for novel targeted pathway and alternative therapeutic modalities for treating HCC.
The Hedgehog (Hh) pathway is a major tissue growth regulator. The pathway is activated by the binding of mammalian Hh ligands (Sonic Hh, Indian Hh and Desert Hh) to Patched (Ptch1) which relieves its inhibition on Smoothened (Smo), culminating in the nuclear localization of DNA-binding Gli transcription factors. These transcription factors lead to production of Hh target genes, such as Ptch1 and Gli1, which also serve as convenient readouts of pathway activation. Together these components generally function to control tissue development of many tissue types. (7) (8) (9) . For example, in the fetus this signaling pathway functions early in the endoderm to establish hepatic progenitor cells (10) . However, Hh signaling appears to have a far more significant role in maintaining hepatic progenitors in the adult liver (11, 12) (13) . The Hh pathway is activated during liver regeneration (13) and in response to chronic liver injury (11, 12, 14, 15) .
Inappropriate activation of Hh pathway has been implicated in several gastrointestinal tumor types (16) . Several studies have demonstrated aberrant Hh signaling in human HCC tissues and cell lines. Hh signaling appears to be particularly active in the setting of chronic liver disease and might partially account for the common occurrence of HCC in the setting of chronic liver disease and cirrhosis (17, 18).
Blockade of Hh signaling results in decreased proliferation and migration, and an increase in apoptosis of human HCC cell lines (19-26). Other groups have implicated
Hh transcriptional targets as critical to tumor progression and metastasis (21, 23) .
Of the multiple small molecule Hh inhibitors currently undergoing evaluation in clinical trials, all are Smo antagonists (27) (32) . In particular, HPI-1 is a potent antagonist of Gli proteins (Gli-1 and 2) and also blocks Hh signaling in the setting of exogenous Gli expression. However it might be difficult to translate these in vitro findings to in vivo studies since this inhibitor has poor systemic bioavalibility. Its lipophilic nature and poor aqueous solubility make it difficult to deliver in vivo. We developed and characterized(33) a novel polymeric nanoparticle encapsulating HPI-1 (NanoHHI).
In this study we first established the clinical significance of Ptch1 expression in HCC, as a marker of downstream Hh activity. We show Ptch1 expression in patients undergoing curative HCC resection correlated with early recurrence and was a poor prognostic feature. Further, we show that NanoHHI is effective at inhibiting the proliferation and motility of two human HCC cell lines in vitro, and significantly inhibits subcutaneous tumor growth at least as effectively as the current standard-of-care chemotherapeutic agent, sorafenib. Notably, however, NanoHHI is remarkably more effectively than sorafenib at inhibiting metastasis in a lethal orthotopic model of human HCC. The ability to potently suppress systemic metastasis is likely attributed to the ability of NanoHHI to significantly down regulate CD133-expressing cells, which are implicated as tumor initiating cells in HCC. These studies provide early evidence of a nanoparticle encapsulated agent that might be useful for chemotherapy in 
Materials and Methods

Patients and Specimens
Tumor specimens used in TMAs were obtained from 396 HCC patients who underwent surgical resection at the Liver Cancer Institute, Zhong Shan Hospital, Fudan University from Feb 1st, 2000 to Dec 1st, 2002. Tumor specimens were taken from viable areas of the tumors; necrotic tissues were avoided. The inclusion criteria of all the patients in this study were (1) confirmed histopathological diagnosis of HCC based on the WHO criteria (34); (2) without any prior therapy; (3) with an "intent-to-cure" surgical resection, which is defined as the complete resection of all tumor nodules and the margins being free of cancer by histological examination(35); (4) with suitable formalin-fixed, paraffin-embedded tissues; and (5) patients with demographic and clinicopathological follow-up data. Tumor differentiation was defined according to the Edmondson grading system (36). Liver function was assessed by the Child-Pugh classification. Tumor staging was defined according to the sixth edition of TNM classification of UICC.
The clinicopathological characteristics of all the patients were summarized in Table 1 . Ethical approval for human subjects was obtained from the research ethics committee of Zhong Shan
Hospital and the Johns Hopkins University Institutional Review Board.
Follow-up and Tumor Recurrences
Patients were followed up every 2 months during the first postoperative year and at Most patients died from recurrence or metastasis, or complicated liver cirrhosis.
Patients with confirmed recurrence received further treatment, which followed the same protocol based on the size, site, number of tumor nodules and liver function.
Briefly, if the recurrent tumor was localized, a second liver resection, radiofrequency ablation (RFA), or percutaneous ethanol injection (PEI) was performed; if the recurrent tumor was multiple or diffuse, then transcatheter arterial chemoembolization (TACE) was the choice. External radiotherapy was given if lymph node or bone metastasis was found. Otherwise, symptomatic treatment was provided. Overall survival (OS) was defined as the interval between surgery and death or the last observation taken. The data were censored at the last follow-up for living patients.
Time to recurrence (TTR) was measured from the date of resection until the detection of recurrent tumor and data were censored for patients without signs of recurrence.
Tissue Microarray and Immunohistochemistry
TMA was constructed as previously described (37) . Briefly, all the HCC and peritumoral liver tissues were reviewed by two histopathologists, and representative areas free from necrotic and hemorrhagic materials were pre-marked in the paraffin blocks. Two core biopsies of 1mm in diameter were taken from the donor blocks and transferred to the recipient paraffin block at defined array positions. Two HCC and 2 respective peritumoral liver TMA blocks were constructed. Consecutive sections of 4-μm thickness were taken on 3-aminopropyltriethoxysilane (APES)-coated slides (Shanghai Biochip Co., Ltd., Shanghai, P.R.China). The rabbit polyclonal antibody for Ptch1 was purchased from Santa Cruz Biotechnology, Santa Cruz, CA (No.sc-6149, diluted 1:100). Immunohistochemistry was carried out using a two-step protocol (Novolink Polymer Detection System, Novocastra, Newcastle, UK) as previously described (37, 38) . Briefly, after microwave antigen retrieval, tissues were incubated with primary antibodies for 60 min at room temperature or overnight at (Supplemental Figure S1) . All of the cases with different scorings were discussed at a multi-headed microscope until consensus was reached. The duplicate of spots for each tumor showed relative homogeneity for stained cell percent and intensity.
Evaluation of Immunohistochemical Variables
The higher score was considered as a final score in case of a difference between duplicate tissue cores.
Drugs Formulations
NanoHHI was engineered as described (33) . Sorafenib was purchased from Bayer Pharmaceutical Corporation, and dissolved in sterile DMSO and stored frozen under light-protected conditions at -20 o C.
Cell culture
Huh7, HepG2, and MHCC97L (97L) human HCC cell lines were used in these studies.
Huh7 and hepG2 were purchased from America Type Culture Collection. 97H and 97L were provided by Dr. Xin-Wei Wang from U.S. National Cancer Institute with the permission of Prof. Zhao-You Tang of Liver Cancer Institute, Fudan University, China.
All the cell lines were routinely maintained were maintained at 37℃ and 5% CO2 in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
In vitro Growth and Matrigel Invasion Assay
Cell proliferation was assessed using the MTT assay. Cells were seeded at a containing NanoHHI (40μM), sorafenib (10μM) or NanoHHI (40μM)+sorafenib (10μM) for the cell invasion assay and incubated for 8 h at 37℃. The cells that actively migrated to the lower surface of the filters were stained and quantified.
All assays were performed in triplicate.
In vivo preclinical studies on NanoHHI efficacy
Male athymic BALB/c nu/nu mice, 4 -6 wk old, were purchased from Jackson
Laboratory. All studies on mice were conducted in accordance with the National Institutes of Health "Guide for the Care and Use of Laboratory Animals". The study protocol was approved by Medical Experimental Animal Care Committee of Johns Hopkins University. Subcutaneous and orthotopic HCC models were established as described before (25) . Briefly, approximately 5×10 6 Huh7 cells in 0.2 ml culture medium were injected subcutaneously into the right flank of athymic mice, which were then observed daily for signs of tumor development. Once the subcutaneous tumor reached 1 cm in diameter, it was removed and freshly minced into pieces about 2mm 3 , which were implanted into the liver of athymic mice, using the method as described previously (25) . The subcutaneous and orthotopic models were administered drugs beginning at day 7 following tumor cell injection or tumor implantation. Twenty subcutaneous and 20 orthotopic tumor mice were randomly assigned to four experimental groups. The four experimental groups were as follows: untreated control group, NanoHHI (30mg/kg, i.p, twice a day for 4 weeks), sorafenib (20mg/kg, orally take by gavage in 1% DMSO, twice a day for 4 weeks) treatment group, and NanoHHI combined sorafenib treatment group (administered by using the same schedule for each drug as described for the single treatment). 
QRT-PCR, Western blot, and Flow cytometry
Total RNA was prepared using Trizol (Invitrogen), and then cDNA was synthesized using the Superscript First-Strand Synthesis system (Invitrogen). Quantitative real time qRT-PCR amplification for human Gli-1 (hGli1), Gli-2 (hGli2), and murine Gli1
Research. 
Results
Expression of Ptch1 and Relevance to Prognostic Factors
There are reports of Hh signaling components expressed in human HCC tissues, however, these results have not been linked to clinical outcome (21, 39) . We Compared to control staining, Ptch1 was detected predominantly in the cytoplasm of tumor cells, and was also present to a lesser extent at the cell membrane ( Figure   1A-D) . Ptch1 expression in tumor tissue correlated with patient age of presentation, tumor encapsulation and recurrence ( Table 2 ). For the whole study population, the 5-year overall survival (OS) and time to recurrence (TTR) rates were 53.4% and 46.3% respectively. On univariate analysis, significant poor predictors of OS included serum HBsAg; Child-Pugh score; serum GGT and AFP; tumor encapsulation, size and number; vascular invasion; TNM and BCLC stage ( 
NanoHHI inhibits HCC cell proliferation and invasion in vitro
We wanted to determine if suppressing downstream Hh activity with a potent Gli inhibitor could inhibit the in vitro growth of HCC cell lines (33) . We found NanoHHI significantly (P<0.029) suppressed Huh7 cell growth compared to vehicle control and to a comparable degree as sorafenib (Figure 2A) . In another human HCC cell line, MHCC-97L, sorafenib significantly suppressed in vitro growth, while, NanoHHI showed some growth suppression, but this was not statistically different than control (P>0.05) (Figure 2A) . Since downstream Hh activity is associated with HCC invasion (21, 23) we next measured the ability of NanoHHI to inhibit invasion. We found NanoHHI significantly suppressed the ability of both Huh7 and MHCC-97L cells to invade into Matrigel compared to vehicle treatment (Figure 2B & 2C) . Similarly, 
sorafenib significantly inhibited HCC invasion in vitro in both cell lines, with a minor but not statistically significant additive effect when cells were treated with both NanoHHI and sorafenib (Figure 2B & 2C) .
NanoHHI potently inhibits HCC growth and metastasis in vivo
One week after subcutaneous injection of the Huh7 cell line into athymic mice, they Figure 3C ). The treated xenografts demonstrated significant reduction in hGli1 and hGli2 as well as murine Gli1 and Gli2 (mGli1, mGli2) levels ( Figure 3D, E) .
Of note, there was no significant decrease in hGli1, hGli2 or mGli1, mGli2 expression in the sorafenib treated xenografts. In tumors receiving combination therapy there was significant suppression of hGli1 and mGli2
For orthotopic xenograft studies, a sterile 2mm 3 Figure 3B) . Remarkably, only 2 metastases were found in 2 mice of NanoHHI group ( Figure 3B ). These were satellite, intrahepatic spread of tumors that were physically discontinuous from the initial tumor implant and not distant metastasis. Similarly, only 3 total metastatic lesions were found in the mice treated with both NanoHHI and sorafenib ( Figure 3B ). Taken as a whole, these data show that NanoHHI treatment potently suppresses HCC metastases.
NanoHHI decreases the population of CD133 positive HCC cells.
To begin to understand how NanoHHI could suppress metastatic spread, we examined CD133 expression since it has been linked to Hh signaling and identifies a subpopulation of cancer initiating cells which could account for formation of metastasis(19). First we found NanoHHI treatment significantly downregulated combination treatment also showed a decrease in CD133. Since CD133 expression is not unique to cancer initiating cells (19, 40, 41), we also looked at these treatments on Huh7 cells in vitro. We saw sorafenib treatment did not show a significant inhibition of CD133, while NanoHHI and combination treatment with both agents did significantly downregulate CD133 transcription (Figure 3G) . This was also true after extended sorafenib treatment period at more than one dose (Supplemental Figure S2) . Flow cytometry analysis showed that NanoHHI significantly decreased the population of CD133 positive cells compared with control (4.5% vs. 21.1%, P<0.01, Figure 3I ).
Again, sorafenib showed a trend to decreased CD133 surface expression but it was not statistically significant. have been linked to HCC differentiation and the functional significance of these polymorphisms is not clear (39) . Finally, the downstream Hh target, GLI1 is amplified in cancers but has not been specifically described in HCC (28, 29) . For these reasons, we aimed to suppress the downstream Hh target Gli-1.
To suppress Gli activity we turned to HPI-1, a molecule Hyman and colleagues uncovered in a screen of small molecules aimed at suppressing Hh activity downstream of Smo (32) . However, the native HPI-1 molecule is lipophilic and not water soluble which will likely translate into poor bioavailability. Therefore we used a polymeric nanoparticle encapsulated formulation (NanoHHI) which has been developed as a non-toxic, safe for in vivo studies Gli inhibitor(33).
We found NanoHHI significantly inhibited HCC proliferation and invasion to a similar degree as sorafenib in vitro. A striking difference was seen in vivo, with NanoHHI 
potently suppressing metastatic spread while sorafenib had practically no effect. A recent report addressed a similar question (49) . Like Feng and Wang, we both show sorafenib decreases tumor growth in vivo. However, they show a much more significant effect of sorafenib on tumor metastasis than we do. A key difference between these studies is their utilization of partial hepatectomy to remove the primary tumor before initiating sorafenib therapy. These therapies need not be mutually exclusive since they target different pathways. Combination therapy with sorafenib and NanoHHI showed comparable rates of metastasis as Nanno HHI alone ( Figure   2B) , with, the combination of agents still suppressing Gli1 and Gli2 derived from the tumor cells ( Figure 3D ). This is not entirely surprising since it is likely multiple pathways contribute to HCC metastasis. Together this suggests Hh activity could account for a bad prognosis and increased tumor dissemination and taken with our in vivo metastasis data, suggests suppressing Gli activity might improve the dismal recurrence rates in HCC.
The possible mechanism of the anti-metastasis efficacy of NanoHHI includes, 1) Inhibition of Hh signaling pathway which has been confirmed as one of the important pathway of cancer initiating / stem cell in our previous studies (unpublished observation and (23) 
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Abbreviations: 95%CI, 95% confidence interval; RFS, Relapse-free survival; OS, overall survival. AFP, alpha-fetoprotein; GGT, gamma-glutamyl transpeptidase; ALT, alanine aminotransferase; TACE, transcatheter arterial chemoembolization; TNM, tumor-node-metastasis; BCLC, Barcelona Clinic Liver Cancer; Ptch1, protein patched homolog 1.
Research. n.a. n.a. Abbreviations: OS, overall survival; RFS, relapse-free survival; 95%CI, 95% confidence interval; GGT, gamma-glutamyl transpeptidase; BCLC, Barcelona Clinic Liver Cancer; Ptch1, protein patched homolog Multivariate analysis, Cox proportional hazards regression model. The clinicopathological variables were adopted for their prognostic significance by univariate analyses.
n.a. n.a. n.a. n.a. n.a. n.a.
